Krka, d. d. (LJSE:KRKG)

Market Cap	7.40B +42.5%
Revenue (ttm)	2.04B +6.9%
Net Income	403.24M +13.0%
EPS	13.21 +13.9%
Shares Out	30.31M
PE Ratio	18.47
Forward PE	18.61
Dividend	8.25 (3.38%)
Ex-Dividend Date	Jul 21, 2026

Volume	1,876
Average Volume	3,731
Open	241.00
Previous Close	244.00
Day's Range	240.00 - 244.00
52-Week Range	173.50 - 251.00
Beta	0.46
RSI	64.71
Earnings Date	May 14, 2026

About Krka, d. d.

Krka, d. d., a generic pharmaceutical company, develops, produces, markets, and sells prescription pharmaceuticals, non-prescription products, and animal health products in Slovenia, South-East Europe, East Europe, Central Europe, West Europe, and internationally. The company offers prescription pharmaceuticals for cardiovascular, central nervous system, gastrointestinal tract, pain, diabetes, and other therapeutic areas. It also provides non-prescription products for cough, cold, cerebral, peripheral circulation, gastrointestinal tract, metabo...

• Industry: Pharmaceutical Preparations
• Founded: 1954
• Employees: 11,667
• Stock Exchange: Ljubljana Stock Exchange
• Ticker Symbol: KRKG

Financial Performance

In 2025, Krka, d. d.'s revenue was 2.04 billion, an increase of 6.89% compared to the previous year's 1.91 billion. Earnings were 403.24 million, an increase of 12.96%.